🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Renaissance Technologies (RenTech)’s SPRY Holdings & Trades

First Buy
Q3 2021
Duration Held
15 Quarters
Largest Add
Q1 2022
+302,542 Shares
Current Position
174,200 Shares
$750,802 Value

Renaissance Technologies (RenTech)'s SPRY Position Overview

Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 174,200 shares of ARS Pharmaceuticals, Inc. (SPRY) worth $750,802, representing 0.00% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 15 quarters.

Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in SPRY, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 302,542 shares. Largest reduction occurred in Q3 2022, reducing 234,899 shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies (RenTech)'s ARS Pharmaceuticals (SPRY) Holding Value Over Time

Track share changes against reported price movement

Quarterly ARS Pharmaceuticals (SPRY) Trades by Renaissance Technologies (RenTech)

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +174,200 New Buy 174,200 $4.31
Q4 2024 -15,800 Sold Out 0 $0.00
Q3 2024 -108,300 Reduce 87.27% 15,800 $14.50
Q2 2024 +111,500 Add 884.92% 124,100 $8.51
Q1 2024 -39,400 Reduce 75.77% 12,600 $10.24
Q4 2023 -85,700 Reduce 62.24% 52,000 $5.48
Q3 2023 -166,600 Reduce 54.75% 137,700 $3.78
Q2 2023 -26,300 Reduce 7.96% 304,300 $0.01
Q1 2023 +19,600 Add 6.30% 330,600 $0.01
Q4 2022 -3,400 Reduce 1.08% 311,000 $0.01
Q3 2022 -234,899 Reduce 42.76% 314,400 $5.28
Q2 2022 -121,243 Reduce 18.08% 549,299 $4.24
Q1 2022 +302,542 Add 82.21% 670,542 $3.51
Q4 2021 +251,400 Add 215.61% 368,000 $6.66
Q3 2021 +116,600 New Buy 116,600 $9.98

Renaissance Technologies (RenTech)'s ARS Pharmaceuticals Investment FAQs

Renaissance Technologies (RenTech) first purchased ARS Pharmaceuticals, Inc. (SPRY) in Q3 2021, acquiring 116,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies (RenTech) has held ARS Pharmaceuticals, Inc. (SPRY) for 15 quarters since Q3 2021.

Renaissance Technologies (RenTech)'s largest addition to ARS Pharmaceuticals, Inc. (SPRY) was in Q1 2022, adding 670,542 shares worth $2.35 M.

According to the latest 13F filing for Q3 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 174,200 shares of ARS Pharmaceuticals, Inc. (SPRY), valued at approximately $750,802.

As of the Q3 2026 filing, ARS Pharmaceuticals, Inc. (SPRY) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies (RenTech)'s peak holding in ARS Pharmaceuticals, Inc. (SPRY) was 670,542 shares, as reported at the end of Q1 2022.